Varex Imaging (NASDAQ:VREX) Updates Q3 2026 Earnings Guidance

Varex Imaging (NASDAQ:VREX) updated its third quarter 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.150-0.300 for the period, compared to the consensus estimate of 0.220. The company issued revenue guidance of $210.0 million-$225.0 million, compared to the consensus revenue estimate of $215.5 million.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on VREX. Weiss Ratings reissued a “sell (d-)” rating on shares of Varex Imaging in a research note on Friday, March 27th. Wall Street Zen cut Varex Imaging from a “buy” rating to a “hold” rating in a research note on Saturday. Jefferies Financial Group restated a “hold” rating and set a $14.50 price target on shares of Varex Imaging in a research report on Monday, February 2nd. B. Riley Financial reaffirmed a “buy” rating on shares of Varex Imaging in a research note on Thursday, February 12th. Finally, Zacks Research upgraded shares of Varex Imaging from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.17.

Varex Imaging Price Performance

NASDAQ VREX opened at $9.83 on Friday. Varex Imaging has a 12 month low of $6.76 and a 12 month high of $14.56. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.89 and a quick ratio of 1.87. The firm has a market capitalization of $411.88 million, a PE ratio of -4.92 and a beta of 0.96. The company’s 50 day simple moving average is $11.55 and its 200 day simple moving average is $12.17.

Varex Imaging (NASDAQ:VREX) last announced its earnings results on Thursday, May 7th. The company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.01). Varex Imaging had a negative net margin of 9.64% and a positive return on equity of 8.21%. The firm had revenue of $216.00 million for the quarter, compared to the consensus estimate of $216.92 million. Varex Imaging has set its Q3 2026 guidance at 0.150-0.300 EPS. As a group, equities research analysts forecast that Varex Imaging will post 0.93 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Jay K. Kunkel sold 4,510 shares of the firm’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $11.14, for a total transaction of $50,241.40. Following the completion of the transaction, the director owned 23,450 shares of the company’s stock, valued at $261,233. This trade represents a 16.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.60% of the stock is owned by corporate insiders.

Varex Imaging News Roundup

Here are the key news stories impacting Varex Imaging this week:

• Neutral Sentiment: Varex reported Q2 revenue of $216 million and adjusted EPS of $0.21, both just below consensus, while the company said demand remained solid and margins held relatively steady. Varex Announces Financial Results for Second Quarter Fiscal Year 2026
• Neutral Sentiment: The company’s GAAP results were weaker, with a net loss of $0.19 per diluted share and $2 million in cash outflows from operations, which may keep some pressure on the stock despite stable gross margins. Varex Announces Financial Results for Second Quarter Fiscal Year 2026
• Negative Sentiment: Varex’s Q3 fiscal 2026 guidance called for EPS of $0.15 to $0.30 versus analysts’ $0.22 estimate, and revenue guidance of $210 million to $225 million versus about $215.5 million expected, signaling only modest upside and likely disappointing investors looking for a stronger outlook. Varex Announces Financial Results for Second Quarter Fiscal Year 2026
• Negative Sentiment: Coverage from earnings transcript and analysis pieces on Yahoo Finance, Seeking Alpha, and Zacks all centered on the earnings and revenue miss, reinforcing the market’s negative reaction to the quarterly update. Varex Imaging (VREX) Q2 2026 Earnings Transcript

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VREX. Millennium Management LLC boosted its stake in Varex Imaging by 119.8% during the third quarter. Millennium Management LLC now owns 913,169 shares of the company’s stock valued at $11,323,000 after buying an additional 497,650 shares in the last quarter. Qube Research & Technologies Ltd boosted its stake in Varex Imaging by 2,514.9% during the second quarter. Qube Research & Technologies Ltd now owns 318,127 shares of the company’s stock valued at $2,758,000 after buying an additional 305,961 shares in the last quarter. Deerfield Management Company L.P. bought a new position in Varex Imaging during the third quarter valued at about $3,537,000. Essex Investment Management Co. LLC bought a new position in Varex Imaging during the fourth quarter valued at about $3,196,000. Finally, JPMorgan Chase & Co. boosted its stake in Varex Imaging by 381.8% during the third quarter. JPMorgan Chase & Co. now owns 284,227 shares of the company’s stock valued at $3,524,000 after buying an additional 225,238 shares in the last quarter.

About Varex Imaging

Varex Imaging Corporation is a global provider of X-ray imaging components and solutions for the medical, security and industrial markets. The company designs, develops and manufactures a broad range of products that convert X-ray energy into high-resolution digital images. Its portfolio includes X-ray tubes, flat panel detectors, digital sensors, specialty radiographic tubes and related software, all engineered to meet the demanding requirements of original equipment manufacturers (OEMs) in diagnostic imaging, computed tomography (CT), fluoroscopy, mammography, dental radiography and non-destructive testing applications.

The company’s medical imaging offerings support a wide spectrum of clinical modalities, from portable radiography systems to advanced CT scanners, enhancing image quality and dose efficiency for healthcare providers.